By inhibiting NF‐kB (a transcription factor that stimulates inflammatory genes), omega‐3 fatty acids suppress lipogenesis‐related SREBP‐1c (sterol regulatory element‐binding protein 1c) and LXR (liver‐x receptor), and decrease MMP‐9 levels in patients with MS and inflammatory processes, resulting in reducing the risk of or improving the condition of MS (AlAmmar et al. 2021). This evidence concerns the gene SREBF1 and myeloid sarcoma.